Table 5

Mean life time health outcomes, costs and average and incremental cost-effectiveness ratios (CERs) for the drug combinations in a scenario with very high CV risk. Incremental CERs are in addition reported for the high, medium and low CV risk scenarios. 95% confidence intervals are reported in brackets for the ICERs.

Very high CV risk

Incremental CERs (USD/DALY)

Intervention

Life years saved (nominal)

Costs

DALYs

ACER (USD/DALY)

ICER (USD/DALY)

High risk

Medium risk

Low risk

Asa

1.6

138

0.8

163

(Dominated)

DiuVhigh

1.6

74

0.9

85

85 (61 – 133)

135 (95 – 212)

149 (105 – 230)

232 (163 – 266)

Bet

0.6

107

0.3

329

(Dominated)

Cab

0.7

444

0.4

1095

(Dominated)

Sta

2.7

882

1.6

540

(Dominated)

AsaDiu

3.1

175

1.6

111

143 (108 – 197)

222 (146 – 314)

242 (182 – 337)

377 (280 – 530)

AsaBet

2.2

208

1.1

182

(Dominated)

DiuBet

2.2

141

1.1

124

(Dominated)

AsaDiuBet

3.6

250

1.8

138

317 (169 – 3900)

532 (265 – *)

601 (305 – *)

1009 (465 – *)

AsaDiuSta

4.9

1123

2.6

431

(Dominated)

DiuBetSta

4.6

1086

2.5

433

(Dominated)

AsaBetSta

4.4

1143

2.4

481

(Dominated)

AsaDiuBetSta

5.4

1229

2.8

440

999 (752 – 1376)

1588 (1175–2190)

1739 (1270–2420)

2749 (2010–3850)

Poly

6.3

1755

3.2

557

1476 (545–8000)

2466 (856–16800)

2735 (932–19500)

4589 (1450–51000)

* > 100 000

Robberstad et al. Cost Effectiveness and Resource Allocation 2007 5:3   doi:10.1186/1478-7547-5-3